A phase II evaluation of @entity16418 and @entity4316 in the treatment of advanced XXXX in adults.

@entity1 @entity242 @entity4316 @entity2615 @entity3 @entity16418
Twenty-nine @entity1 with @entity3 were treated with a combination of @entity16418 and @entity4316 . @entity1 with adequate bone marrow reserve received @entity16418 100 mg/m2 orally on day 1 and @entity4316 0.3 mg/m2/day intravenously for five days. Both drugs were repeated every four weeks. @entity1 with inadequate bone marrow reserve received @entity16418 75 mg/m2 and @entity4316 0.2 mg/m2/day for five days. All @entity1 had received prior chemotherapy and had progressive disease at the start of the study. There was one complete response in a @entity1 with peritoneal @entity2615 which lasted 18 months and the @entity1 is still alive at 38+ months. Ten @entity1 had stable disease including three @entity1 who had responses between 25% to 50%. No responses were seen in 18 @entity1 . The median time to progression for @entity1 with stable disease was five months and for those with progressive disease was two months (P = 0.001). The median survival for @entity1 with stable disease was 20 months compared with three months for @entity1 with progressive disease (P = 0.001). The combination was generally very well tolerated and myelosuppression was insignificant. However, with the dosages and schedule used in this study, the combination of @entity16418 and @entity4316 does not appear to have significant activity in advanced soft tissue @entity242 . Further studies with this combination are indicated in @entity1 with @entity2615 .
